If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
=== EC 1.2.5 With a quinone or similar compound as acceptor === EC 1.2.5.1: pyruvate dehydrogenase (quinone) EC 1.2.5.2: aldehyde dehydrogenase (quinone) EC 1.2.5.3: aerobic carbon monoxide dehydrogenase
== Diagnosis == Joint hypermobility syndrome shares symptoms with other conditions such as Marfan syndrome and Ehlers-Danlos Syndrome. Hypermobility syndrome and Hypermobile Ehlers-Danlos syndrome are difficult to diffentiate, and the boundaries between them may be arbitrary. Hypermobility syndrome and hypermobile Ehlers-Danlos syndrome are both likely to have a variety of genetic causes. Generalized hypermobility is a common feature in hereditary connective tissue disorders and many features overlap, but often features are present that enable differentiating these disorders. Ehlers-Danlos Syndrome was defined based on its observable symptoms in the skin and joints. The inheritance pattern of Ehlers-Danlos syndrome varies by type. The arthrochalasia, classic, hypermobility and vascular forms usually have an autosomal dominant pattern of inheritance. Autosomal dominant inheritance occurs when one copy of a gene in each cell is sufficient to cause a disorder. In some cases, an affected person inherits the mutation from one affected parent. Other cases result from new (sporadic) gene mutations. Such cases can occur in people with no history of the disorder in their family. It is impossible to tell whether a person has EDS symptoms due to an inherited EDS gene, a spontaneous mutation that causes identical symptoms, or a problem in fetal development causes identical symptoms, without both knowing the genetic family history and performing a specialized genetic test. The results do not matter to clinical treatment of the symptoms.
== Lipid storage == Lipids are stored in white adipose tissue as triglycerides. In a lean young adult human, the mass of triglycerides stored represents about 10–20 kilograms. Triglycerides are formed from a backbone of glycerol with three fatty acids. Free fatty acids are activated into acyl-CoA and esterified to finally reach the triglyceride droplet. Lipoprotein lipase has an important role.
Sources: en.wikipedia.org
=== EC 1.7.99 With other acceptors === EC 1.7.99.1: hydroxylamine reductase EC 1.7.99.2: deleted: reaction may have been due to the combined action of EC 1.7.99.6 nitrous-oxide reductase and EC 1.7.99.7 nitric-oxide reductase EC 1.7.99.3: Now included with EC 1.7.2.1, nitrite reductase (NO-forming) EC 1.7.99.4: Now EC 1.7.1.1, nitrate reductase (NADH), EC 1.7.1.2, nitrate reductase [NAD(P)H], EC 1.7.1.3, nitrate reductase (NADPH), EC 1.7.5.1, nitrate reductase (quinone), EC 1.7.7.2, nitrate reductase (ferredoxin) and EC 1.9.6.1, nitrate reductase (cytochrome) EC 1.7.99.5: Now included with EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.7.99.6: Now EC 1.7.2.4 nitrous-oxide reductase EC 1.7.99.7: Now EC 1.7.2.5 nitric oxide reductase (cytochrome c) EC 1.7.99.8: hydroxylamine oxidoreductase EC 1.7.99.8: Now classified as EC 1.7.2.8, hydrazine dehydrogenase
=== Pulp Tissue Extension === There is dental pulp extending to the tip of the root, which tapers towards the apical foramen. The Odontoblast processes may extend slightly into the root dentin near the apex. Nerve fibres in this region are mostly unmyelinated, with some myelinated fibres (Aδ and C fibres) entering via the foramen. Blood vessels for example: arterioles, venules, and capillaries anastomose with vessels in the periodontal ligament.
=== Inland taipan === The inland taipan (Oxyuranus microlepidotus) is considered the most venomous snake in the world with a murine LD50 value of 0.025 mg/kg SC. Ernst and Zug et al. 1996 list a value of 0.01 mg/kg SC, which makes it the most venomous snake in the world in their study too. They have an average venom yield of 44 mg. Bites from this species have a mortality rate of 80% if left untreated, although it is very rare for this species to bite. This species is known to be a very shy, reclusive and a laid-back snake that will nearly always slither away from disturbance. It is not an aggressive species and rarely strikes. No recorded incidents have been fatal since the advent of the monovalent (specific) antivenom therapy.
== Regional actors == Saudi Arabia and the United Arab Emirates share the US and Israel's stated objectives of restricting Iran's nuclear, drone and missile programs, though they differ on whether war or diplomacy is the best path. According to The Washington Post, crown prince and Prime Minister of Saudi Arabia Mohammed bin Salman had urged Trump to attack Iran in multiple phone calls, and that the Saudi Arabian and Israeli governments lobbied Trump repeatedly to make the move in the weeks leading up to the initial strikes. It has also been reported that Saudi Arabia pushed Trump to continue the war against Iran until its government is overthrown. These allegations were denied by Saudi Arabia.
Sources: en.wikipedia.org
In 1949, its genetic transmission was determined by E. A. Beet and J. V. Neel. In 1954, it was established that carriers of the abnormal gene are protected to some degree against malaria, which accounts for its persistence in populations threatened by malaria.
Webber (1995), professor of law at Boston University School of Law Barry Scott Wimpfheimer (1995), professor of religious studies at Northwestern University, expert on the Talmud Lara Bazelon (1996), professor of law at University of San Francisco School of Law Gabriella Coleman (1996), anthropologist known for her work in hacker culture and online activism; professor at McGill University Elena Conis (1996), historian of medicine at University of California, Berkeley Leah DeVun (1997), professor of gender studies at Rutgers University Jessica Greenberg (1997), social anthropologist and professor at University of Illinois at Urbana–Champaign Lauren Winner (1997), historian, professor at Duke Divinity School Brooke Holmes (1998), classicist, professor at Princeton University Alison Gass (1998), former chief curator of the Cantor Arts Center, director of the Smart Museum of Art and the Institute of Contemporary Art San José Louis Hyman (1999), economic historian, professor at Cornell University School of Industrial and Labor Relations, author of Debtor Nation Adrianne Wadewitz (1999), feminist scholar and noted Wikipedian Yehuda Kurtzer (2000), president of the Shalom Hartman Institute, son of ambassador Daniel C.
With the advent of induced pluripotent stem cells (iPSC), treatments being explored and created for the used in endangered low production animals possible. Rather than needing to harvest embryos or eggs, which are limited, the researchers can remove mesenchymal stem cells with greater ease and greatly reducing the danger to the animal due to noninvasive techniques. This allows the limited eggs to be put to use for reproductive purposes only.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.